Ligand-based CAR-T cell : Different strategies to drive T cells in future new treatments
Ramírez-Chacón, Alejandro (Universitat Autònoma de Barcelona. Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí")
Betriu-Méndez, Sergi (Institut d'Investigacions Biomèdiques August Pi i Sunyer)
Bartoló-Ibars, Ariadna (Institut d'Investigacions Biomèdiques August Pi i Sunyer)
González, Azucena (Institut d'Investigacions Biomèdiques August Pi i Sunyer)
Martí, Mercè (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia)
Juan, Manel (Hospital Sant Joan de Déu (Barcelona, Catalunya))

Date:	2022
Abstract:	Chimeric antigen receptor (CAR)-based therapies are presented as innovative treatments for multiple malignancies. Despite their clinical success, there is scientific evidence of the limitations of these therapies mainly due to immunogenicity issues, toxicities associated with the infusion of the product, and relapses of the tumor. As a result, novel approaches are appearing aiming to solve and/or mitigate the harmful effects of CAR-T therapies. These include strategies based on the use of ligands as binding moieties or ligand-based CAR-T cells. Several proposals are currently under development, with some undergoing clinical trials to assess their potential benefits. In addition to these, therapies such as chimeric autoantibody receptor (CAAR), B-cell receptor antigen for reverse targeting (BAR), and even chimeric human leukocyte antigen (HLA) antibody receptor (CHAR) have emerged, benefiting from the advantages of antigenic ligands as antibody-binding motifs. This review focuses on the potential role that ligands can play in current and future antitumor treatments and in other types of diseases, such as autoimmune diseases or problems associated with transplantation.
Grants:	Instituto de Salud Carlos III PI18/00775 Instituto de Salud Carlos III PICI18/00012
Note:	Aquest article té una correcció a 10.3389/fimmu.2022.1078003
Note:	Altres ajuts: Complementary grant for CONCORD-023, Fondo Europeo de Desarrollo Regional (FEDER) "una manera de hacer Europa", "La Caixa" Foundation (CP042702/LCF/PR/GN18/50310007), Secretaria d'Universitats i Recerca del Departament d'Empresa i Coneixement, Generalitat de Catalunya, project 2020PANDE00079
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	T cells ; Chimeric Antigen Receptor (CAR) ; Ligands ; Receptor ; Antigen ; CAAR ; BAR
Published in:	Frontiers in immunology, Vol. 13 (September 2022) , art. 932559, ISSN 1664-3224

Correcció de l'article: https://ddd.uab.cat/record/272266
DOI: 10.3389/fimmu.2022.932559
PMID: 36172370

17 p, 1.6 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Biotecnologia i de Biomedicina (IBB)
Articles > Research articles
Articles > Published articles